Open main menu

Psychiatrienet β

Citalopram-hypericum

Revision as of 12:08, 7 May 2009 by Alexandra (talk | contribs) (Created page with '{{ Drugswitch | from = citalopram | to = hypericum | stop = * '''Before day 0:''' gradually reduce dosage of citalopram/escitalopram to a maximum of 20 mg/day, resp. 10 mg/day...')
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Citalopram
Type Antidepressant
Group SSRI
links
ATC-code N06AB04
Medscape Citalopram
PubChem 2771
PubMed Citalopram
Kompas (Dutch) citalopram
Wikipedia citalopram
Hypericum
Type Antidepressant
Group other
links
EMEA 10130408en
PubMed Hypericum
Kompas (Dutch) hypericum extract
Wikipedia St John's wort

Switch medication from citalopram to hypericum.[1] [2]

Nietinrijdenbord.png Stop citalopram
  • Before day 0: gradually reduce dosage of citalopram/escitalopram to a maximum of 20 mg/day, resp. 10 mg/day.
  • Day 1: reduce dosage of citalopram/escitalopram to 10 mg/day, resp. 5 mg/day.
  • Day 8: stop administration of citalopram/escitalopram.
Eenrichtingbord.png Start hypericum
  • Day 8-14: a wash-out period of one week is necessary.
  • Day 15: start administration of hypericum in a dosage of 300 mg three times a day (900 mg/day).
Infobord.png More information
  • Occurrence of serotonin syndrome is theoretically possible, so caution is necessary.
  • Hypericum slows the metabolism of citalopram/escitalopram via CYP3A4.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.